Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Mathilde Couetoux du Tertre"'
Autor:
Karen Gambaro, Maud Marques, Suzan McNamara, Mathilde Couetoux du Tertre, Cyrla Hoffert, Archana Srivastava, Anna Schab, Thierry Alcindor, Adrian Langleben, Lucas Sideris, Mahmoud Abdelsalam, Mustapha Tehfe, Felix Couture, Gerald Batist, Petr Kavan
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 1, p 43 (2023)
Single-agent regorafenib is approved in Canada for metastatic colorectal cancer (mCRC) patients who have failed previous lines of therapy. Identifying prognostic biomarkers is key to optimizing therapeutic strategies for these patients. In this clini
Externí odkaz:
https://doaj.org/article/ec86c695c34645c382ed30a6f5995a36
Autor:
Karen Gambaro, Maud Marques, Suzan McNamara, Mathilde Couetoux du Tertre, Zuanel Diaz, Cyrla Hoffert, Archana Srivastava, Steven Hébert, Benoit Samson, Bernard Lespérance, Yoo‐Joung Ko, Richard Dalfen, Eve St‐Hilaire, Lucas Sideris, Felix Couture, Ronald Burkes, Mohammed Harb, Errol Camlioglu, Adrian Gologan, Vincent Pelsser, André Constantin, Celia M.T. Greenwood, Sabine Tejpar, Petr Kavan, Claudia L. Kleinman, Gerald Batist
Publikováno v:
Clinical and Translational Medicine, Vol 11, Iss 4, Pp n/a-n/a (2021)
Abstract Background Therapeutic resistance is the main cause of death in metastatic colorectal cancer. To investigate genomic plasticity, most specifically of metastatic lesions, associated with response to first‐line systemic therapy, we collected
Externí odkaz:
https://doaj.org/article/2db15e511b2048da941740287e8636c1
Autor:
Zhide Fang, Joseph F. Buell, Hiromi Brown, Gerald Batist, Karen Gambaro, Jonathan Tabak, Sudhir K. Sinha, Mathilde Couetoux du Tertre, Susan McNamara
Publikováno v:
Surgery. 166:534-539
Liquid biopsy is a new area in cancer diagnostics that measures cell-free DNA in plasma from tumor that may serve as a monitoring tool in colorectal cancer patients.Multiplexed real-time polymerase chain reaction based on multicopy retro-transposable
Autor:
Luisa Izzi, H. Wang, Victor Cohen, Christian Couture, Nicole Bouchard, Jason Agulnik, Valerie Higenell, Normand Blais, Lise Tremblay, Cyrla Hoffert, Caroline Rousseau, Mathilde Couetoux du Tertre, Gerald Batist, Razvan Diaconescu, Maud Marques, Suzan McNamara, Vincent Pelsser, Karen Gambaro, Alan Spatz, Archana Srivastava
Publikováno v:
Molecular Cancer Therapeutics. 18:1628-1636
Rearrangements in the anaplastic lymphoma kinase (ALK) gene are found in approximately 5% of non–small cell lung carcinoma (NSCLC). Here, we present a comprehensive genomic landscape of 11 patients with ALK+ NSCLC and investigate its relationship w
Autor:
Mathilde Couetoux du Tertre, Eve St-Hilaire, Archana Srivastava, Steven Hébert, Lucas Sideris, Sabine Tejpar, Bernard Lespérance, Petr Kavan, Claudia L. Kleinman, Yoo-Joung Ko, Richard Dalfen, Karen Gambaro, Adrian Gologan, Gerald Batist, Maud Marques, Celia M. T. Greenwood, André Constantin, Mohammed Harb, Ronald Burkes, Benoit Samson, Suzan McNamara, Vincent Pelsser, Errol Camlioglu, Cyrla Hoffert, Zuanel Diaz, Félix Couture
Publikováno v:
Clinical and Translational Medicine, Vol 11, Iss 4, Pp n/a-n/a (2021)
Clinical and Translational Medicine
Clinical and Translational Medicine
Background Therapeutic resistance is the main cause of death in metastatic colorectal cancer. To investigate genomic plasticity, most specifically of metastatic lesions, associated with response to first‐line systemic therapy, we collected longitud
Autor:
Pascal Croteau, Christian Couture, Mathilde Couetoux du Tertre, Valérie Hindie, Valerie Higenell, Karen Gambaro, Yannick-André Breton, Cyrla Hoffert, Victor Cohen, Lise Tremblay, Maud Marques, Laura McIntosh, Normand Blais, Stephane Parent, Gerald Batist, Hangjun Wang, Alan Spatz, Gwenael Pottiez, Nicole Bouchard, Laetitia Cortes, Vincent Pelsser, Jason Agulnik, Luisa Izzi, Razvan Diaconescu, Suzan McNamara
Publikováno v:
Clinical Proteomics
Background ALK tyrosine kinase inhibition has become a mainstay in the clinical management of ALK fusion positive NSCLC patients. Although ALK mutations can reliably predict the likelihood of response to ALK tyrosine kinase inhibitors (TKIs) such as
Autor:
Mathilde Couetoux du Tertre, Karen Gambaro, Vincent R. Richard, Maud Marques, René P. Zahedi, Bernhard Blank-Landeshammer, André LeBlanc, Alan Spatz, Suzan McNamara, Ingo Feldmann, Gerald Batist, Albert Sickmann, Laxmikanth Kollipara, Georgia Mitsa, Christoph H. Borchers
Publikováno v:
Cancers
Volume 11
Issue 12
Volume 11
Issue 12
Hotspot testing for activating KRAS mutations is used in precision oncology to select colorectal cancer (CRC) patients who are eligible for anti-EGFR treatment. However, even for KRASwildtype tumors anti-EGFR response rates are <
30%, while mu
30%, while mu
Autor:
Mahmoud Adbelsalam, Maud Marques, Suzan McNamara, Archana Srivastava, Anna schab, Karen Gambaro, Sophie Mathieu, Mustapha Tehfe, Cyrla Hoffert, Mathilde Couetoux du Tertre, Gerald Batist, Thierry Alcindor, Lucas Sideris, Adrian Langleben, Petr Kavan
Publikováno v:
Cancer Research. 80:4325-4325
Single-agent regorafenib is approved in Canada and in the US for patients with metastatic colorectal cancer (mCRC) who have failed previous lines of therapy1. Identification of prognostic biomarkers is crucial to ensure the best therapeutic strategie
Autor:
Jas Khattra, Maud Marques, Melissa K. McConechy, Adrian Kense, Madeline Couse, Sonal Brahmbhatt, Ruth R. Miller, Rosalia Aguirre Hernandez, Salem Malikic, Kevin Tam, Suzan McNamara, Ka Mun Nip, Mathilde Couetoux du Tertre, Karen Gambaro, David G. Huntsman, Gerald Batist
Publikováno v:
Clinical Cancer Research. 26:A07-A07
The Exactis trial (NCT00984048), assessed plasma circulating-tumor DNA (ctDNA) mutations and whether they correlated with their relative levels in metastatic tumor biopsies in 50 mCRC enrolled patients undergoing first-line treatment. Exactis is a Ca
Autor:
Ryan D. Morin, Sarah E. Arthur, Daniel J. Renouf, Hui-Li Wong, David F. Schaeffer, Miguel Alcaide, Suzan McNamara, Kevin Bushell, Matthew C. Cheung, Mathilde Couetoux du Tertre, Gerald Batist, Joanna M. Karasinska, Hagen F. Kennecke, Aly Karsan
Publikováno v:
The Journal of molecular diagnostics : JMD. 21(2)
Recurrent activating point mutations in KRAS are critical drivers in pancreatic cancer and have been attributed to resistance to anti–epidermal growth factor receptor therapy in colorectal cancer. Although KRAS genotyping provides limited clinical